MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Moleculin Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.27−0.02 (-5.49%)
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Moleculin Biotech statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Market Cap | $5.16M | $166.30M |
| Enterprise Value | -$2.10M | $88.19M |
| PB Ratio | 0.45 | 2.03 |
| P/TBV Ratio | 0.45 | 2.29 |
Income (trailing twelve months)
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$28.87M | -$21.40M |
| Net Income | -$30.33M | -$22.46M |
| EBITDA | -$28.83M | -$16.91M |
| EPS (Diluted) | -$15.01 | -$0.83 |
Returns
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Return on Equity (ROE) | -523.6% | -53.2% |
| Return on Assets (ROA) | -142.1% | -40.9% |
| Return on Capital Employed (ROCE) | -245.2% | -38.1% |
Balance sheet
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.26M | $61.43M |
| Net Cash (Debt) | $7.26M | $15.35M |
| Net Cash Per Share | $0.37 | $0.66 |
| Equity (Book Value) | $11.59M | $49.09M |
| Book Value Per Share | $0.59 | $1.37 |
| Tangible Book Value | $11.59M | $23.52M |
| Working Capital | -$590.00K | $76.81M |
Financial position
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Current Ratio | 0.94 | 3.34 |
| Quick Ratio | 0.78 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.36M | -$12.35M |
Efficiency
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$202 | -$703.34K |
| Employee Count | 150,000 | 74 |
Dividends and yields
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Earnings Yield | -587.6% | -23.3% |
Shares
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 19,477,400 | 58,127,000 |
| Shares Change (YoY) | 906.5% | 10.9% |
| Shares Change (QoQ) | 33.0% | 0.54% |
| Float | 15,377,700 | 49,136,700 |
| Shares Held by Insiders | 21.0% | 11.6% |
| Shares Held by Institutions | 0.95% | 59.4% |
Taxes
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Moleculin Biotech | Industry median |
|---|---|---|
| Altman Z-Score | -19.26 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Moleculin Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.